Abstract
Simple antibodies or vector-induced T cell immunity are unable to provide broad immunity to HIV. Although broadly reactive neutralising antibodies are a goal of vaccination, this remains elusive. There is growing evidence that HIV-specific antibodies that mediate their activity via the Fc-receptor, such as antibody dependent cellular cytotoxicity (ADCC), have an important role in controlling HIV infection. Newer assays are being developed that enable HIV-specific ADCC responses to be finely mapped. In turn, this should allow a more definitive analysis of the effectiveness of HIVspecific ADCC antibodies. However, progressive dysfunction of effector cells that mediate ADCC responses, such as NK cells, combined with immune escape variants that emerge from effective ADCC responses, likely undermine the utility of ADCC responses during chronic HIV infection. Nonetheless the utility of ADCC responses in preventing HIV infection requires urgent consideration.
Keywords: HIV, antibodies, ADCC, vaccine
Current HIV Research
Title: The Utility of ADCC Responses in HIV Infection
Volume: 6 Issue: 6
Author(s): Amy Chung, Erik Rollman, Susanne Johansson, Stephen J. Kent and Ivan Stratov
Affiliation:
Keywords: HIV, antibodies, ADCC, vaccine
Abstract: Simple antibodies or vector-induced T cell immunity are unable to provide broad immunity to HIV. Although broadly reactive neutralising antibodies are a goal of vaccination, this remains elusive. There is growing evidence that HIV-specific antibodies that mediate their activity via the Fc-receptor, such as antibody dependent cellular cytotoxicity (ADCC), have an important role in controlling HIV infection. Newer assays are being developed that enable HIV-specific ADCC responses to be finely mapped. In turn, this should allow a more definitive analysis of the effectiveness of HIVspecific ADCC antibodies. However, progressive dysfunction of effector cells that mediate ADCC responses, such as NK cells, combined with immune escape variants that emerge from effective ADCC responses, likely undermine the utility of ADCC responses during chronic HIV infection. Nonetheless the utility of ADCC responses in preventing HIV infection requires urgent consideration.
Export Options
About this article
Cite this article as:
Chung Amy, Rollman Erik, Johansson Susanne, Kent J. Stephen and Stratov Ivan, The Utility of ADCC Responses in HIV Infection, Current HIV Research 2008; 6 (6) . https://dx.doi.org/10.2174/157016208786501472
DOI https://dx.doi.org/10.2174/157016208786501472 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gq protein-Coupled Receptors as Targets for Anesthetics
Current Pharmaceutical Design Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Fatty Acid Amide Hydrolase Inhibitors – Progress and Potential
CNS & Neurological Disorders - Drug Targets Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
Current Cardiology Reviews GABA<sub>B</sub> Agonists for the Treatment of Alcohol Use Disorder
Current Pharmaceutical Design Recent Advances in the Medicinal Chemistry of Aurones
Current Medicinal Chemistry Harnessing Natural Resources for Advancements in Dengue Virus Treatment
Current Topics in Medicinal Chemistry Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology A Systematic Review of the Literature of the Three Related Disease Entities Cheilitis Granulomatosa, Orofacial Granulomatosis and Melkersson – Rosenthal Syndrome
Current Pediatric Reviews The Role of Anticoagulation in Cancer Patients: Facts and Figures
Anti-Cancer Agents in Medicinal Chemistry The Role of Cytokines in Atopic Asthma
Current Medicinal Chemistry Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial [Hot topic: Models and Evolution of Inflammatory Activities (Executive Editor: Giuseppe Scapigliati)]
Current Pharmaceutical Design